Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma.
Saved in:
| Title: | Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma. |
|---|---|
| Authors: | Jaime-Casas S; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Barragan-Carrillo R; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Zugman M; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Shah K; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Ebrahimi H; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Mercier B; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Castro DV; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Zang PD; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., LeVee A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Yip W; Division of Urology and Urologic Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Li X; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Dizman N; Department of Hematology and Oncology, MD Anderson Cancer Center, Houston, TX, United States., Salgia NJ; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Zengin Z; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States., Meza L; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States., Hsu J; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Nguyen CB; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Chehrazi-Raffle A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Pal SK; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States., Tripathi A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Oct 07; Vol. 15, pp. 1669526. Date of Electronic Publication: 2025 Oct 07 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1669526 |
